The stock is a high-risk, binary bet on the company's ability to survive. Traders should monitor the Nasdaq compliance deadline of September 8, 2026, and the outcome of the €12M grant application, expected in July 2026. A failure on either front could lead to a delisting or a severe equity raise, causing significant dilution.
Price Chart
Executive Summary
Scinai Immunotherapeutics' 20-F filing reveals a company in transition, shifting from a struggling biopharma to a dual CDMO/R&D model. Despite a $1.6M cash position and recurring CDMO revenues, the company faces substantial doubt about its going concern status due to a $8.3M net loss and a Nasdaq delisting threat from a sub-$1 bid price. The company is attempting to secure a $12M non-dilutive grant for its PC111 program and has restructured its debt, converting a $29M loan into preferred shares. Its stock is at high risk of delisting.
Key Facts
- The company has $1.6M in cash as of Dec 31, 2025, which is insufficient to fund operations for the next 12 months, leading to a 'going concern' qualification.
- The company reported a net loss of $8.3M for 2025, with $6.0M in negative cash flow from operations.
- The company's stock is in danger of Nasdaq delisting for failing to maintain a $1.00 minimum bid price, a notice received on March 12, 2026.
- The company's CDMO business generated $1.3M in revenue in 2025, up from $0.7M in 2024, but is not yet profitable.
- The company is attempting to secure a €12M non-dilutive grant for its PC111 program, with a revised application submitted on March 30, 2026.
- The company restructured its debt with the EIB, converting $29M of debt into preferred shares, leaving a nominal $260K outstanding.
Financial Impact
The company's cash burn and Nasdaq delisting risk are immediate threats to its survival. The failure to secure the €12M grant would severely impact its R&D pipeline.
Risk Factors
- The company may be delisted from Nasdaq if it fails to regain compliance with the $1.00 minimum bid price by September 8, 2026.
- The company's cash reserves are critically low, and it will require additional financing, likely on dilutive terms, to continue operations.
- The company's revised grant application for PC111 may be rejected, which would be a major setback for its primary R&D program.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001213900-26-038011 |
| Document: ea028360901ex1-1.htm | 0001213900-26-038011 |
| Document: ea028360901ex4-16.htm | 0001213900-26-038011 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $0.6813 | awaiting T+60 | — | $0.5310 (−22.06%) |
Oct 16, 2026 11d ago | 6-K | $0.7520 | awaiting T+60 | — | $0.5310 (+29.39%) |
Oct 16, 2026 11d ago | Press Release | $0.7524 | awaiting T+60 | — | $0.5310 (+29.43%) |
Oct 15, 2026 12d ago | 6-K | $0.9015 | awaiting T+60 | — | $0.5310 (+41.10%) |
Oct 13, 2026 14d ago | 6-K | $1.23 | awaiting T+60 | — | $0.5310 (−56.83%) |
Oct 6, 2026 22d ago | EFFECT | $1.22 | awaiting T+60 | — | $0.5310 (+56.48%) |
Sep 21, 2026 5w ago | 6-K | $1.69 | awaiting T+60 | — | $0.5310 (−68.58%) |
Aug 26, 2026 8w ago | 6-K | $2.87 | awaiting T+60 | — | $0.5310 (+81.50%) |
Aug 19, 2026 9w ago | 6-K | $0.2740 | awaiting T+60 | — | $0.5310 (−93.80%) |
Jun 17, 2026 18w ago | 6-K | $0.3370 $0.2440 | ▼ −27.60% | ▼ −30.28% | $0.5310 (+57.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers